Oragenics Working on Treatment for Oral Mucositis With Promising AG013 Product (Proactive)

Oragenics Working on Treatment for Oral Mucositis With Promising AG013 Product

Alan Joslyn, CEO of UF startup and UF Innovate | Sid Martin Biotech alum Oragenics, Inc., a Tampa-based company leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), talked with Proactive’s Steve Darling at the 12th annual LD Micro Conference. The company is developing the AG013, which is in clinical trials for the treatment of OM or ulcerative lesions in patients with cancer.

 

Learn more about Oragenics Working on Treatment for Oral Mucositis With Promising AG013 Product.

Related news:

Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis.

Oragenics Making ‘Great Progress’ Enrolling Patients in Oral Mucositis Clinical Trial.

Oragenics Presents Interim Data on the AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019.
X